Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcourakis, T.
Right arrow Articles by Gentil, V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marcourakis, T.
Right arrow Articles by Gentil, V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 7, No. 4, 325-330 (1993)
DOI: 10.1177/026988119300700403

Clomipramine, a better reference drug for panic/agoraphobia. II. Psychomotor and cognitive effects

T. Marcourakis

Centro de Investigações em Neurologia, Faculdade de Medicina USP, Departamento de Farmacologia, Instituto de Ciências Biomédicas USP

C. Gorenstein

Departamento de Farmacologia, Instituto de Ciências Biomédicas USP

V. Gentil

Departamento de Psiquiatria, LIM-23, Faculdade de Medicina, Universidade de São Paulo, Brazil

The present reference drugs for the treatment of panic disorder and agoraphobia are imipramine and alprazolam. The latter decreases performance and cognitive functioning. No study of such functions in panic/agoraphobia is available. Fifty four out-patients meeting DSM-III-R criteria for panic disorder with or without agoraphobia (PAG), taking part in a parallel groups controlled trial of imipramine (mean dose ±SEM 114±9 mg), clomipramine (50±4 mg) and propanteline (active placebo) over 8 weeks, were studied. A test battery of psychomotor and memory tests was administered at baseline, and after 1, 4 and 8 weeks of treatment. Their results were compared (at baseline and at the end of the trial) with those of a control group of 57 normal untreated subjects. There was no difference between treatments, and no drug effect on any test at any time. No consistent difference between patients and controls was detected. Given its apparently higher potency, and the absence of deleterious effects on cognitive measures known to be affected by benzodiazepines, we conclude that clomipramine is better than imipramine or alprazolam as a reference drug for panic/agoraphobia.

Key Words: imipramine • clomipramine • panic disorder • memory • psychomotor performance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
C. Gorenstein, M.A. Bernik, S. Pompeia, and T. Marcourakis
Impairment of performance associated with long-term use of benzodiazepines
J Psychopharmacol, January 1, 1995; 9(4): 313 - 318.
[Abstract] [PDF]